We may earn a commission for purchases through links on our site at no cost to you, Learn more. All trademarks and brand names are the property of their respective owners. All Wegovy product and service names used in this website are for informational purposes only. Use of these names and brands does not imply endorsement.
- Wegovy (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists used for weight loss.
- Clinical trials show Wegovy is generally more effective for weight loss than Saxenda.
- In a 68-week study, Wegovy users lost 16% of initial body weight compared to 6% for Saxenda users.
- Both medications work by mimicking GLP-1 to reduce appetite and slow gastric emptying.
- Wegovy is administered once weekly, while Saxenda requires daily injections.
- Both drugs can cause similar side effects, primarily gastrointestinal issues, but Wegovy appears to be better tolerated.
- Both medications are most effective when combined with lifestyle changes like improved diet and increased physical activity.
- Individual responses to these medications can vary, and patients should consult healthcare providers before starting treatment.
- Wegovy and Saxenda have shown cardiovascular benefits and weight loss effects.
Wegovy (semaglutide) appears to be more effective for weight loss than Saxenda (liraglutide), with studies indicating greater weight reduction and better tolerance among users.
However, individual responses to these GLP-1 receptor agonists can vary, and both medications are FDA-approved for weight management in certain adults and adolescents with obesity.
How Saxenda and Wegovy work
Saxenda (liraglutide) and Wegovy (semaglutide) are GLP-1 receptor agonists that mimic the hormone GLP-1 to reduce appetite and slow gastric emptying. These medications act on the brain’s appetite control centers, promoting feelings of fullness and reducing hunger.
They also enhance insulin function, which helps lower blood sugar levels and can benefit individuals with type 2 diabetes. While both drugs have similar mechanisms, Wegovy’s once-weekly dosing compared to Saxenda’s daily injections may contribute to its potentially greater effectiveness and better adherence rates.
The slight differences in their molecular structures may also account for variations in their efficacy and side effect profiles.
Clinical trial comparisons: Saxenda vs. Wegovy
Clinical trials have demonstrated that Wegovy (semaglutide) generally outperforms Saxenda (liraglutide) in terms of weight loss efficacy.
A 68-week study comparing the two medications in 300 adults found that participants taking Wegovy achieved more significant weight loss, losing 16% of their initial body weight compared to 6% for those on Saxenda.
Additionally, the STEP 1 clinical trials showed that 50% of participants using Wegovy lost at least 15% of their initial body weight. Both medications have shown cardiovascular benefits, but Wegovy appears to be better tolerated with fewer adverse events and side effects.
However, it’s important to note that individual responses can vary, and both medications are most effective when combined with lifestyle changes such as improved diet and increased physical activity.
Side effects: What to expect from each medication
Both Saxenda (liraglutide) and Wegovy (semaglutide) can cause similar side effects, with gastrointestinal issues being the most common. For Saxenda, the most frequently reported side effects include nausea, diarrhea, constipation, vomiting, headache, and fatigue.
These effects are typically mild to moderate and often improve over time. Wegovy users may experience similar gastrointestinal side effects, but studies suggest they are generally better tolerated than Saxenda.
Both medications carry risks of more serious side effects, including pancreatitis, gallbladder problems, and potential thyroid tumors. It’s crucial for patients to discuss their medical history with healthcare providers before starting either medication and to report any persistent or severe side effects promptly.